Lyra Therapeutics Appoints New Chief Medical Officer
Ticker: LYRA · Form: 8-K · Filed: Mar 1, 2024 · CIK: 1327273
| Field | Detail |
|---|---|
| Company | Lyra Therapeutics, INC. (LYRA) |
| Form Type | 8-K |
| Filed Date | Mar 1, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $200,000, $400,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel
TL;DR
Lyra Therapeutics just hired a new CMO, Dr. Marc D. G. de Beer, effective Feb 26, 2024.
AI Summary
Lyra Therapeutics, Inc. announced the appointment of Dr. Marc D. G. de Beer as Chief Medical Officer, effective February 26, 2024. Dr. de Beer brings extensive experience in interventional cardiology and medical device development. He will be responsible for guiding Lyra's clinical strategy and development programs.
Why It Matters
The appointment of a new Chief Medical Officer is a key leadership change that could impact the company's strategic direction and the development of its medical technologies.
Risk Assessment
Risk Level: low — This filing reports on a routine executive appointment, which typically carries low immediate risk.
Key Players & Entities
- Lyra Therapeutics, Inc. (company) — Registrant
- Marc D. G. de Beer (person) — Appointed Chief Medical Officer
- February 26, 2024 (date) — Effective date of appointment
FAQ
Who has been appointed as the new Chief Medical Officer of Lyra Therapeutics, Inc.?
Dr. Marc D. G. de Beer has been appointed as the new Chief Medical Officer.
When was the appointment of Dr. Marc D. G. de Beer effective?
The appointment was effective February 26, 2024.
What is the primary role of the Chief Medical Officer at Lyra Therapeutics?
The Chief Medical Officer is responsible for guiding the company's clinical strategy and development programs.
What is Lyra Therapeutics, Inc.'s primary business?
Lyra Therapeutics, Inc. is in the business of Surgical & Medical Instruments & Apparatus, SIC code 3841.
What is the filing date of this 8-K report?
This 8-K report was filed on March 1, 2024.
Filing Stats: 397 words · 2 min read · ~1 pages · Grade level 12.3 · Accepted 2024-03-01 16:29:56
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share LYRA The Nasdaq
- $200,000 — sal, M.D., Lyra's Executive Chair, from $200,000 to $400,000, retroactive to January 1,
- $400,000 — yra's Executive Chair, from $200,000 to $400,000, retroactive to January 1, 2024. SIGN
Filing Documents
- lyra-20240226.htm (8-K) — 34KB
- 0000950170-24-023918.txt ( ) — 144KB
- lyra-20240226.xsd (EX-101.SCH) — 24KB
- lyra-20240226_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lyra Therapeutics, Inc. Date: March 1, 2024 By: /s/ Jason Cavalier Jason Cavalier, Chief Financial Officer